Integra LifeSciences Holdings Corporation

IART Healthcare Medical Devices

Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.21 0.32 −2.37%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
26.1×
Dividend yield
—
F-score
5/9
Altman Z
0.62
Beneish M
−3.25
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(0.70%) (38.64%) (39.90%) (38.71%)

+8 more TTM periods

Piotroski F-Score
5 5 5 5
ROA
(0.20%) (13.00%) (13.52%) (12.85%)
ROIC
1.58% (11.20%) (11.87%) (11.73%)
Return on Tangible Assets
(0.55%) (38.98%) (44.99%) (40.70%)
Average Days of Receivables
59.19 58.69 62.24 58.24
Free Cash Flow per Share
0.33 0.05 (0.40) (0.06)
Free Cash Flow
25.80 4.08 (31.05) (4.51)
Other line items

Show all line items

Columns are period end dates